research on retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide Analog GLP-3RT Research Peptide

It produces greater improvements in lipid profile and inflammatory markers

The combination produced 24.2% weight loss at the 12mg dose in Phase 2 trials, the highest reported for any GLP-1 class medication so far

While GLP-1s can reduce appetite and cravings, pairing treatment with supportive lifestyle habits and following nutrition tips from your clinician often makes changes feel more noticeable and sustainable

Novo Nordisk has confirmed that Phase III trials for Amycretin will begin in early 2026

The triple-agonist mechanism, the comparison against semaglutide and tirzepatide and the published trial record are documented on the main Retatrutide page and are not restated here